Blood-based biomarkers for cancer immunotherapy: Tumor mutational burden in blood (bTMB) is associated with improved atezolizumab (atezo) efficacy in 2L+ NSCLC (POPLAR and OAK)
David R. Gandara, Marcin Kowanetz, Tony S.K. Mok et al. · Annals of Oncology · 2017
Cited by 86 works. doi:10.1093/annonc/mdx380 Open-access PDF